Go Pro
OTCMKTS:SARTF

Sartorius Q1 2025 Earnings Report

Sartorius logo
$212.80 0.00 (0.00%)
As of 07/24/2026

Sartorius EPS Results

Actual EPS
$1.28
Consensus EPS
$1.28
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Sartorius Revenue Results

Actual Revenue
$959.23 million
Expected Revenue
$867.08 million
Beat/Miss
Beat by +$92.15 million
YoY Revenue Growth
N/A

Sartorius Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Sartorius Earnings Headlines

The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars and recycle profits into Treasuries. That agreement came up for renewal in June 2024 and quietly lapsed. Since then, Saudi Arabia signed a $7 billion currency swap with China, began settling some oil trades in yuan, and joined Beijing's mBridge payment network. Meanwhile, the 10-year yield is pushing toward 4.4percent on a $39 trillion debt load. Garrett Goggin, CFA and CMT, says gold miners still priced for sub-$2,000 gold could hold the real leverage as this shift plays out.tc pixel
Sartorius (SARTF) to Post Earnings on Thursday
See More Sartorius Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sartorius? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sartorius and other key companies, straight to your email.

About Sartorius

Sartorius (OTCMKTS:SARTF) AG, trading in the U.S. over the counter under the symbol SARTF, is a Germany-based provider of laboratory and bioprocessing equipment for the pharmaceutical, biotechnology and research industries. The company is organized into two core divisions: Bioprocess Solutions, which focuses on single-use consumables, filtration technologies and upstream and downstream processing systems; and Lab Products & Services, which supplies laboratory instruments, consumables and services, including balances, pipettes, cell counting systems and water purification units.

The Bioprocess Solutions segment serves customers engaged in the development and manufacture of biopharmaceuticals, vaccines and advanced therapies. Its product range includes single-use bioreactors, tangential flow filtration systems, media and buffer preparation tools and process analytics. In the Lab Products & Services segment, Sartorius offers high-precision laboratory balances, pipetting devices, lab filtration products and software-driven services aimed at improving workflow efficiency and data integrity in quality control and R&D laboratories.

Founded in 1870 in Göttingen, Germany, Sartorius has expanded its global footprint with production and service sites across Europe, North America and Asia. The company supports research institutions, contract development and manufacturing organizations (CDMOs) and major pharmaceutical manufacturers in over 100 countries. Its executive board is chaired by Dr. Joachim Kreuzburg, under whose leadership Sartorius has pursued both organic growth and strategic acquisitions to strengthen its technology portfolio and international presence.

View Sartorius Profile